Evotec and Eternygen announced a drug discovery collaboration to develop novel metabolic disease therapy.
The two companies will develop novel small molecule inhibitors against an Eternygen target to treat metabolic disease using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development.
Eternygen is working on the sodium coupled citrate transporter NaCT, a novel target which is a key regulator of energy metabolism involved in the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis ("NASH"), diabetes and obesity.
NaCT is also known as INDY (“I am Not Dead Yet”). To accelerate its small molecule NaCT inhibitors towards the selection of a pre-clinical lead candidate, Eternygen will use the proceeds of the Series A funding.
NaCT is an attractive therapeutic target for the treatment of non-alcoholic fatty liver disease, obesity, and type 2 diabetes by influencing the mammalian energy metabolism.
Eternygen will rely on Evotec's best-in-class drug discovery platform and metabolic disease expertise to conduct all work to the selection of pre-clinical development candidate and possibly beyond.
Developing novel metabolic disease therapy using advanced technology improves human health worldwide.
